Colesevelam‐induced hypoglycaemia in a patient with type 1 diabetes mellitus
Abstract Colesevelam possesses antidiabetic properties, which could potentiate sulphonylurea or insulin‐induced hypoglycemia; clinically significant hypoglycemia, as a side effect to bile acid sequestrants, may be under‐recognized in clinical practice.
Guardado en:
Autores principales: | Panagiotis Pavlou, Vaios Koutroukas, Catherine Lissett, Jamie C. Smith |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/99ee04b4939d493592638149b96eed73 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Frequency of Diabetic Ketoacidosis and Severe Hypoglycemia in Children with Type 1 Diabetes
por: A Homaei, et al.
Publicado: (2022) -
Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
por: Kushner P
Publicado: (2010) -
The value of patient-reported outcomes in patients with type 2 diabetes mellitus receiving insulin therapy: assessment of quality of life and hypoglycemia problems
por: Tat'yana Ivanovna Ionova, et al.
Publicado: (2015) -
Pharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitus
por: Alla Vsevolodovna Rudakova
Publicado: (2011) -
Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach
por: Pollock RF, et al.
Publicado: (2018)